Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.22 USD | +3.40% | -0.73% | +122.95% |
05-13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
05-08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+122.95% | 571M | |
+69.51% | 62.86B | |
-0.83% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.22% | 26.46B | |
-22.26% | 18.9B | |
+4.80% | 12.67B | |
+23.86% | 12.27B | |
+28.25% | 12.07B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Transcript : Mind Medicine Inc., Q1 2022 Earnings Call, May 16, 2022